OrbiMed Closes A $950m Fund As Biotech VC Surge Continues
This article was originally published in Scrip
Executive Summary
The health care-focused venture capital firm OrbiMed has raised its largest VC fund to date totaling $950m and if prior investment patterns are repeated as much as $760m of that could be invested in companies focused on the development of drugs or gene therapies.